Daicel (TSE:4202) Lifts Guidance And Dividends, Is The Upside Already Priced In?

Daicel (TSE:4202) is back in focus after releasing first quarter results, issuing fresh earnings guidance for fiscal 2026 to 2027, and outlining higher planned dividends for upcoming quarters.

See our latest analysis for Daicel.

At a share price of ¥1,450.5, Daicel has delivered a 17.97% 90 day share price return. Its 1 year total shareholder return of 13.54% and 5 year total shareholder return of 105.92% point to momentum building over a longer horizon.

If Daicel’s latest results have sharpened your interest in materials and industrial trends, this can be a good moment to broaden your search and check out 10 top founder-led companies

Daicel now pairs clearer earnings guidance and higher planned dividends with a strong multi segment business. After the recent share price move, is the stock already pricing that strength fairly or still leaving upside on the table for new buyers?

Preferred P/E of 37.3x for Daicel: Is it justified?

Daicel trades on a P/E of 37.3x, which sits above several reference points and signals that the market is paying a premium for its earnings.

The P/E ratio compares the current share price to earnings per share and is a common way investors think about what they are paying for current profitability. For a diversified chemicals and materials group like Daicel, it can reflect how the market weighs near term earnings pressure against expectations for future profit growth.

According to recent data, the stock is described as expensive relative to the JP Chemicals industry average P/E of 12.6x and a peer average of 17.1x. It is also flagged as expensive compared to an estimated fair P/E of 21.5x, which is a level the market could move toward if expectations cool. At the same time, Daicel is assessed as trading at ¥1,450.5, which is 26.9% below an estimated fair value of ¥1,983.42 based on the SWS DCF model.

Relative to sector and peer benchmarks, Daicel’s 37.3x multiple is meaningfully higher. This suggests the market is currently putting a richer price on each yen of earnings than those comparison groups.

Explore the SWS fair ratio for Daicel

Result: Price-to-Earnings of 37.3x (OVERVALUED)

However, investors should watch for any reversal in Daicel’s recent net income growth, as well as potential pressure on key segments like High Performance Polymers.

Find out about the key risks to this Daicel narrative.

Another View on Daicel’s Value

The earlier P/E workup paints Daicel as expensive, yet the SWS DCF model points the other way. At ¥1,450.5, the stock is assessed as trading 26.9% below an estimated fair value of ¥1,983.42. That highlights potential upside if those cash flow assumptions hold. Which signal do you put more weight on?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Daicel for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 19 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If the mix of potential risks and rewards around Daicel feels finely balanced, take the time to review the underlying data and form your own view. To see both sides in one place, start with the 2 key rewards and 4 important warning signs

Looking for more investment ideas beyond Daicel?

If Daicel has sharpened your focus on opportunities, do not stop here. Broaden your watchlist now so you are not relying on a single story.

• Target potential mispricing by scanning 19 high quality undervalued stocks that combine quality fundamentals with room for the market to reassess their worth.
• Strengthen your income angle with 42 dividend fortresses that focus on higher yielding companies which may appeal if you want regular cash returns.
• Prioritise resilience by reviewing 58 resilient stocks with low risk scores that screen for stocks assessed with lower risk scores and steadier profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com